一项关于重组组织型纤溶酶原激活剂治疗系统性硬化症指端缺血的双盲安慰剂对照试验。
A double blind placebo controlled trial of recombinant tissue plasminogen activator in the treatment of digital ischemia in systemic sclerosis.
作者信息
Klimiuk P S, Kay E A, Illingworth K J, Gush R J, Taylor L J, Baker R D, Perkins C, Jayson M I
机构信息
Rheumatic Diseases Centre, University of Manchester, Salford, U.K.
出版信息
J Rheumatol. 1992 May;19(5):716-20.
PMID:1613700
Abstract
The treatment of digital ischemia in systemic sclerosis remains inadequate. We report a double blind, placebo controlled trial of recombinant tissue plasminogen activator (rtPA), a potent thrombolytic agent. Ten patients received rtPA. A potent, acute fibrinolytic effect was observed. During the infusion of rtPA, improvements in skin blood flow were seen. These improvements were shortlived.
摘要
系统性硬化症中手指缺血的治疗仍然不足。我们报告了一项关于重组组织型纤溶酶原激活剂（rtPA）的双盲、安慰剂对照试验，rtPA是一种有效的溶栓剂。10名患者接受了rtPA治疗。观察到了显著的急性纤溶效果。在输注rtPA期间，皮肤血流有所改善。但这些改善是短暂的。
Zotero 插件